Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | IDH2 | P48735 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965744 | 0.83 | LMNA (0.55) | CNR2ALDH1A1RXFP1LMNAMAPT | |
| SCHEMBL30288260 | 0.74 | RXFP1 (0.54) | ALDH1A1PIM1RXFP1LMNAMAPT | |
| SCHEMBL15162933 | 0.74 | EPHX2 (0.67) | ALDH1A1RXFP1CCR2LMNAMAPT | |
| SCHEMBL30366730 | 0.73 | ALDH1A1 (0.61) | ALDH1A1GRK2LMNAMAPTXBP1 | |
| SCHEMBL4936005 | 0.72 | CNR2 (0.71) | CNR2 | |
| SCHEMBL12476496 | 0.72 | CA12 (0.41) | CNR2PIM1PIM2CCR2LMNA | |
| SCHEMBL30288262 | 0.72 | RXFP1 (0.61) | ALDH1A1PIM1RXFP1LMNAMAPT | |
| SCHEMBL1241128 | 0.72 | RXFP1 (0.61) | ALDH1A1PIM1RXFP1LMNAMAPT | |
| SCHEMBL4931244 | 0.72 | CNR2 (1.00) | CNR2 | |
| SCHEMBL883366 | 0.72 | MAPT (0.59) | ALDH1A1GRK2LMNAMAPTXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | CNR2 3734/4885ALDH1A1 4491/4885PIM1 313/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | CNR2 3734/4885ALDH1A1 4491/4885PIM1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.